<code id='AD993847B6'></code><style id='AD993847B6'></style>
    • <acronym id='AD993847B6'></acronym>
      <center id='AD993847B6'><center id='AD993847B6'><tfoot id='AD993847B6'></tfoot></center><abbr id='AD993847B6'><dir id='AD993847B6'><tfoot id='AD993847B6'></tfoot><noframes id='AD993847B6'>

    • <optgroup id='AD993847B6'><strike id='AD993847B6'><sup id='AD993847B6'></sup></strike><code id='AD993847B6'></code></optgroup>
        1. <b id='AD993847B6'><label id='AD993847B6'><select id='AD993847B6'><dt id='AD993847B6'><span id='AD993847B6'></span></dt></select></label></b><u id='AD993847B6'></u>
          <i id='AD993847B6'><strike id='AD993847B6'><tt id='AD993847B6'><pre id='AD993847B6'></pre></tt></strike></i>

          focus

          focus

          author:entertainment    Page View:89
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Padmanee Sharma of MD Anderson at center of lawsuit over credit
          Padmanee Sharma of MD Anderson at center of lawsuit over credit

          Photoillustration:STAT;Photo:AdobeThreeyearsago,JamieLin,anearly-careernephrologistatMDAndersonCance

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          340B reform proposal comes out of Senate working group

          Sen.JohnThuneisoneofagroupoflawmakersthatisworkingon340Breformlegislation.BRENDANSMIALOWSKI/AFPviaGe